Evidence map›Paper›PMID 38505027›Full record

ReviewJournal of thoracic disease2024

Chylothorax: pathophysiology, diagnosis, and management-a comprehensive review.

Malvika Bhatnagar, Annette Fisher, Sudarshan Ramsaroop, Alison Carter, Benjamin Pippard

Open access · diamondAbstract readReview
In one paragraph

Review in Journal of thoracic disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 4 pooled it
45.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 4 syntheses or guidelines pooled it, 79 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Thoracic duct stenting as a treatment for chylothorax and chylous ascites in patient with Yellow Nail Syndrome.Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia · 2026
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. An unusual case of chylothorax.Breathe (Sheffield, England) · 2026
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Chylothorax after adult cardiac surgery: a comprehensive narrative review.General thoracic and cardiovascular surgery · 2026
    Review

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Malvika BhatnagarDepartment of Respiratory Medicine, South Tyneside and Sunderland NHS Foundation Trust, South Tyneside, UK.
Annette FisherDepartment of Respiratory Medicine, Northumbria Healthcare NHS Foundation Trust, Cramlington, UK.
Sudarshan RamsaroopDepartment of Respiratory Medicine, South Tyneside and Sunderland NHS Foundation Trust, Sunderland, UK.
Alison CarterDepartment of Respiratory Medicine, County Durham and Darlington NHS Foundation Trust, Durham, UK.
Benjamin PippardDepartment of Respiratory Medicine, South Tyneside and Sunderland NHS Foundation Trust, South Tyneside, UK.
South Tyneside and Sunderland NHS Foundation Trust · GBCounty Durham and Darlington NHS Foundation Trust · GBNorthumbria Healthcare NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chylothorax is a rare condition characterized by the accumulation of chyle in the pleural space. While it accounts for a small percentage of pleural effusions, chylothorax can lead to significant morbidity and mortality. This article provides a comprehensive overview of chylothorax, covering its relevant anatomy, aetiology, pathophysiology, clinical features, diagnosis, and management. Injury or disruption to the thoracic duct (which is responsible for chyle transport) leads to the development of chylothorax. This may result from trauma, such as iatrogenic injury during surgery, or non-traumatic causes, including malignancy, lymphatic disorders, and heart failure. Recognition of the underlying cause is essential to tailor management. Clinical presentation varies, with symptoms linked to rate of chyle accumulation and the causative condition. Diagnosis relies on pleural fluid analysis, with demonstration of elevated triglyceride levels (>110 mg/dL) and reduced cholesterol levels (<200 mg/dL) being the key diagnostic criteria employed in clinical practice. Various imaging modalities, including computed tomography (CT) scans and lymphatic-specific investigations, may be utilised to aid identification of the site of chyle leak, as well as determine the likely underlying cause. Chylothorax management is multifaceted, with conservative approaches such as dietary modification and pharmacological interventions often initiated as first-line treatment. Drainage of chylous effusion may be necessary for symptom relief. When conservative methods fail, interventional procedures like thoracic duct ligation or embolization can be considered. Due to the diverse aetiological factors and patient characteristics associated with chylothorax, individualized management strategies are recommended. Nonetheless, management of chylothorax is an evolving field with a paucity of high-quality evidence or standardized guidelines, highlighting the importance of ongoing research and a multidisciplinary approach to optimize individual patient care.

Indexed as

Chylothoraxeffusionpleural disease

Identifiers

PMID38505027
PMCPMC10944732
OpenAlexW4392106265

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.